Project description
Innovative protein stabilisation solution for biotechnological and biomedical applications
Proteins are natural universal building blocks with enormous potential for application for use as targets in disease treatment, point-of-care diagnostics, and protein therapeutics. However, the majority of potential applications are hindered by a lack of efficient straightforward technologies for protein stabilisation. The EU-funded INCYPROnext project aims to deliver a universal protein stabilisation solution for biotechnological and biomedical applications. Incircular in the Netherlands has developed and validated a radically new proprietary technology for protein stabilisation. This innovation allows the stabilisation of a broad range of proteins, delivering minimally modified molecules with preserved functionality. The objective of INCYPROnext is to validate the technology in real-world operations, including pharma, biotech, research, and industrial processes applications.
Objective
Proteins are not only one of life’s main building blocks, but also key tools for many industrial applications, ranging from drug discovery and diagnostics to chemical production processes. The main limitation of proteins is their low stability at non-physiological conditions, as they are commonly required in industrial, medical and biotechnological processes. Consequently, proteins often loose structural integrity and activity under relevant conditions. There are thousands of proteins with large potential, for instance in the context of protein targets related to diseases with high unmet need, point-of-care diagnostics and protein therapeutics. However, many cannot be utilized due to a lack of generally applicable technologies that allow straight-forward and meaningful protein stabilization. To address the challenges associated with protein stabilization, a versatile technology overcoming costly, time-consuming and uncertain trial-and-error approaches is required. The INCYPROnext project aims to provide a universal solution to the stabilization of proteins for biotechnological and biomedical applications. In the frame of the ERC PoC project, INCYPRO, we have developed a radically new technology for stabilizing proteins that has been validated in lab. Our innovation combines structural and molecular biology as well as chemistry to provide a highly effective and efficient technology for the stabilization of a broad range of proteins that are currently impossible to stabilize, delivering minimally modified proteins with a highly stabilized structure and retained functionality. This is an ideal value proposition to play a key role in a growing >170 B€ market, which can allow us to both offer B2B services to customers in the pharma, biotech, research and industrial processes segments, as well as to start our own internal drug discovery and development pipeline. In this EIC Transition project, we will validate the INCYPRO technology in a real operating environment (TRL5).
Fields of science
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC - HORIZON EIC GrantsCoordinator
1081 HZ Amsterdam
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.